Holger Monenschein

发表

Optimization of potency and pharmacokinetic properties of tetrahydroisoquinoline transient receptor potential melastatin 8 (TRPM8) antagonists.

H. Monenschein, M. Bartberger, Yunxin Y Bo, 2014, Journal of medicinal chemistry.

Functionalized Polymers-Emerging Versatile Tools for Solution-Phase Chemistry and Automated Parallel Synthesis.

A. Kirschning, H. Monenschein, R. Wittenberg, 2001, Angewandte Chemie.

Towards the total synthesis of tonantzitlolone––preparation of key fragments and the complete carbon backbone

A. Kirschning, H. Monenschein, C. Beier, 2004 .

Reactions of alkenes, alkynes, and alkoxyallenes with new polymer-supported electrophilic reagents

A. Kirschning, H. Monenschein, Katherine Schubothe, 1999 .

Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid.

Yuan Cheng, Wenge Zhong, Michael D Bartberger, 2012, Journal of medicinal chemistry.

Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.

R. Wahl, S. Hitchcock, Yuan Cheng, 2012, Journal of medicinal chemistry.

A Potent and Orally Efficacious, Hydroxyethylamine-Based Inhibitor of β-Secretase.

Yuan Cheng, Yi Luo, Wenge Zhong, 2012, ACS medicinal chemistry letters.

Hydroxyethylamine-based inhibitors of BACE1: P₁-P₃ macrocyclization can improve potency, selectivity, and cell activity.

R. Wahl, S. Hitchcock, M. Citron, 2013, Bioorganic & medicinal chemistry letters.

Structure guided P1' modifications of HEA derived β-secretase inhibitors for the treatment of Alzheimer's disease.

S. Hitchcock, H. Monenschein, M. Bartberger, 2012, Bioorganic & medicinal chemistry letters.

Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia.

H. Monenschein, A. Amador-Arjona, J. Bliesath, 2021, Journal of medicinal chemistry.

Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.

E. Hu, R. Kunz, N. Chen, 2014, Bioorganic & medicinal chemistry.

Total synthesis of apoptolidin: completion of the synthesis and analogue synthesis and evaluation.

K. Nicolaou, P. Giannakakou, A. O'brate, 2003, Journal of the American Chemical Society.

First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate.

H. Monenschein, S. Kikuchi, Nidhi Kaushal, 2021, Journal of medicinal chemistry.

Discovery of TRPM8 Antagonist ( S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic Acid (AMG 333), a Clinical Candidate for the Treatment of Migraine.

H. Monenschein, M. Horner, M. Bartberger, 2018, Journal of medicinal chemistry.

Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease

Justin Powell, H. Monenschein, S. Sheardown, 2021, The Journal of Pharmacology and Experimental Therapeutics.